Medizone Intl. (fka MZEIQ)

[Whatisvalue]

Gelati, the need for AS is understood.

In the US, the hospital bed utilization rate from 1990 to 2012 ranged from about 69.5% to 65.2%, and is declining as the ACA moves providers to outcome-based medicine. So, in the US, there isn't some frantic need to turn beds around upon patient discharge. While it would be nice to see the AS application time reduced, in my view, given the bed overcapacity, it isn't paramount. I acknowledge that situation isn't global. The point of the prior post is that the cost of this excess capacity has to be absorbed by patients treated, including HAI patients; hence the cost to treat these patients may well be higher, for this and other reasons, in the US versus other locals. Simply, the cost structure to treat patients, including HAI patients in the US, shouldn't be casually applied elsewhere when trying to define MZEI's value proposition.

https://www.google.com/search?q=2015+HOSPITAL+BED+UTILIZATION+RATES&rls=com.microsoft:en-US:IE-Address&biw=1504&bih=1272&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwiMl4PRrM3KAhVY3mMKHbcMAisQsAQIOA&dpr=0.75#imgrc=TmXTyrFENWEYiM%3A

Because of significant bed capacity (at least in the US), I question the preference of Dr. Shannon to tinker with the O3 light emitter (so as to shorten application times) versus engaging in the conduct of trials that will prove more significant to defining market economics, business model and company valuation. But what do I know?